Skip to content

CATT study reinforces equivalency between Avastin (bevacizumab) and Lucentis (ranibizumab) at year 2

In May 2011, a long-awaited pronouncement from the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) Research Group, showed that, after 1 year treatment of wet age related macular degeneration, the monthly use of either Avastin (bevacizumab) or Lucentis (ranibizumab) resulted in the same visual acuity outcome. The follow-up 2-year data, announced at this year’s Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale supports a similar conclusion however, debate is set to continue in respect of safety.